Browsing Pathways
Showing 71 -
80 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0125696View Pathway |
Zellweger SyndromeZellweger syndrome, also known as cerebrohepatorenal syndrome, is an autosomal recessive peroxisome biogenesis disorder that is part of the family of Zellweger spectrum disorders. It is caused by a defect in one of 12 or more of the PEX genes (PEX1, 2, 3, 5, 6, 10, 12, 13, 14, 16, 19 and 26) that produce proteins called peroxins. Peroxins are used in the formation of peroxisomes, and can be involved in recognition of proteins targeted for the peroxisome, as well as their transport into the peroxisome. Peroxisomes typically break down both very long chain and branched fatty acids, but if they aren't present, these fatty acids build up in the blood and body, harming organs such as the brain and liver. Additionally, due to the fact that some processes, such as plasmalogen biosynthesis, occur in or using peroxisomes, and can lead to deficiencies in plasmalogens. These are important in brain and lung function, leading to other symptoms. Zellweger syndrome is characterized by an increase in levels of very long chain fatty acids in the blood plasma, as well as more visible physical symptoms, such as an abnormally large or small head at birth, characteristic facial features and poor muscle tone, which can lead to an inability of infants to feed. Other symptoms include an enlarged liver, skeletal abnormalities and low CNS function. Infants very rarely live longer than one year, and the only treatment is for symptoms the patient is experiencing, not for the syndrome itself.
|
Disease
|
|
|
SMP0000316View Pathway |
Zellweger SyndromeZellweger syndrome, also known as cerebrohepatorenal syndrome, is an autosomal recessive peroxisome biogenesis disorder that is part of the family of Zellweger spectrum disorders. It is caused by a defect in one of 12 or more of the PEX genes (PEX1, 2, 3, 5, 6, 10, 12, 13, 14, 16, 19 and 26) that produce proteins called peroxins. Peroxins are used in the formation of peroxisomes, and can be involved in recognition of proteins targeted for the peroxisome, as well as their transport into the peroxisome. Peroxisomes typically break down both very long chain and branched fatty acids, but if they aren't present, these fatty acids build up in the blood and body, harming organs such as the brain and liver. Additionally, due to the fact that some processes, such as plasmalogen biosynthesis, occur in or using peroxisomes, and can lead to deficiencies in plasmalogens. These are important in brain and lung function, leading to other symptoms.
Zellweger syndrome is characterized by an increase in levels of very long chain fatty acids in the blood plasma, as well as more visible physical symptoms, such as an abnormally large or small head at birth, characteristic facial features and poor muscle tone, which can lead to an inability of infants to feed. Other symptoms include an enlarged liver, skeletal abnormalities and low CNS function. Infants very rarely live longer than one year, and the only treatment is for symptoms the patient is experiencing, not for the syndrome itself.
|
Disease
|
|
|
SMP0144613View Pathway |
Zeaxanthin Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0130886View Pathway |
Zeaxanthin Drug MetabolismZeaxanthin is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zeaxanthin passes through the liver and is then excreted from the body mainly through the kidney.
|
|||
SMP0128232View Pathway |
Zea mays pollen Drug Metabolism |
|
||
SMP0145237View Pathway |
Zanubrutinib Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0130872View Pathway |
Zanubrutinib Drug MetabolismZanubrutinib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Zanubrutinib passes through the liver and is then excreted from the body mainly through the kidney.
|
|
||
SMP0129374View Pathway |
Zanthoxylum clava-herculis whole Drug Metabolism |
|
||
SMP0129400View Pathway |
Zanthoxylum clava-herculis bark Drug Metabolism |
|
||
SMP0130196View Pathway |
Zansecimab Drug Metabolism |
|
Showing 71 -
80 of 65006 pathways